MYOV - Myovant Sciences GAAP EPS of -$0.56 beats by $0.08 revenue of $100.23M misses by $2.13M
- Myovant Sciences press release ( NYSE: MYOV ): Q3 GAAP EPS of -$0.56 beats by $0.08 .
- Revenue of $100.23M (+84.1% Y/Y) misses by $2.13M .
- Cash, cash equivalents, marketable securities, and amounts available under the Sumitomo Pharma Loan Agreement totaled $315.7 million in the aggregate as of December 31, 2022, and consisted of $274.4 million of cash, cash equivalents, and marketable securities and $41.3 million of available borrowing capacity under the Sumitomo Pharma Loan Agreement.
For further details see:
Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M